Immunogenicity

The following session will cover immunogenicity, focusing on the definition of immunogenicity and its contrasting roles in vaccines versus therapeutic biologics, highlighting its importance in drug and vaccine development. We will discuss the immune mechanisms underlying immunogenic responses, the factors influencing immunogenicity, and strategies used to predict and minimize unwanted reactions. Finally, we will explore the clinical consequences of immunogenicity, ongoing management approaches, and future innovations aimed at optimizing patient outcomes. Immunogenicity refers to the ability of a substance, such as a therapeutic protein, vaccine antigen or biologic to provoke an immune response. In therapeutics and vaccines, immunogenicity is a double edged sword. With vaccines, a strong lasting response is desirable for protection. While for biologics like monoclonal antibodies, it is usually undesirable as it can affect drug efficacy or safety. Understanding immunogenicity helps in designing safer biologics and more effective vaccines, ultimately improving patient outcomes. The immune system distinguishes self from non self using specialized antigen recognition mechanisms. The innate immune system provides the first defense, detecting broad molecular patterns via receptors like toll like receptors. Dendritic cells and macrophages present antigens on MHC molecules to T cells, activating the adaptive immune system of T and B cells.